Protagonist Therapeutics stock hits new highs with Phase 3 rusfertide data advancing toward FDA approval

Traders Union
All News
Companies
Protagonist Therapeutics up 2.20% today

Highlights

PTGX exhibits a strong bullish trend, consistently trading above key short-, medium-, and long-term support levels.
Technical momentum is positive, with most indicators signaling further upside, though near-term overbought conditions may prompt brief pullbacks.
For the coming week, PTGX is projected to consolidate between $110.30 and $114.60, with breakout potential above recent highs.

Bullish structure as price holds above key averages and Ichimoku support

PTGX is trading at $112.19, above the MA-20 at $100.92, MA-50 at $101.61, and considerably above the MA-200 at $86.45, supporting a strong bullish structure across short-, medium-, and long-term timeframes. The Ichimoku Kijun on D1 is at $102.22, which now acts as immediate support, while near-term support is clustered around the MA-50 ($101.61) and the Kijun ($102.22), and key support sits at MA-100 ($95.92); resistance is defined by the recent 52-week high at $111.69 and the current price zone.

Rising momentum tempered by overbought signals amid strong weekly gains

Momentum remains positive, with MACD on D1 signaling Buy and ADX on D1 indicating a neutral but constructive environment, though weekly ADX is firmly supportive of trend strength. RSI on D1 at 61.59 supports continued upside, but Stoch RSI and CCI on D1 both note overbought conditions, suggesting potential for short-term overextension. BBP on D1 signals solid buyer dominance intraday, which is reinforced by a Bullish signal from the Awesome Oscillator. In today’s session, PTGX is up 2.20% from the prior close, underscoring strong demand, while the past week has seen the stock rise $2.41 (2.19%) from last week's close of $109.78. The price is at the very top of this week's range, and weekly volatility stands at 13.88%. The stock currently trades at new highs after a broad recovery from last week’s low.

Upside probability elevated as unanimous trend signals narrow risk window

For the coming week, PTGX is expected to trade between $110.30 and $114.60, aligning with recent highs and anchoring its range well above the 52-week low of $49.38 and just above the new 52-week high of $111.69. The probability of a further price increase is very high (more than 80%), given the unanimous Buy or Strong Buy signals from MA-50, MACD, ADX, and RSI on the W1 timeframe. The chance of a decline is therefore very low (less than 20%). In the baseline scenario, PTGX consolidates in a narrow band between short-term support and current resistance. In a bullish scenario, a breakout above the $112.33–$114.60 resistance band could open room for a new all-time high. In a bearish scenario, a pullback toward near-term supports at $102.22–$101.61 could occur if overbought momentum triggers profit taking.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Earlier, analysts noted that Protagonist Therapeutics was consolidating with long-term support intact but facing short-term downside pressure following recent volatility. The current article confirms this scenario, highlighting that traders should monitor for a sustained directional move as the stock stabilizes and awaits fresh catalysts.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.